AI Summary & Key Takeaways
AI InsightPDT was found to be safe and effective in preservation of vision and in reducing the probability of severe vision loss due to exudative AMD, but it was found to be inadequate to provide an increase in vision, and in life quality.
📌 3 Key Takeaways
Abstract
Introduction: To investigate and to evaluate the quality of life of the patients with exudative age-related macular degeneration (AMD) by using National Eye Institute Visual Function Questionnaire 25 (NEI-VFQ 25) before and after the photodynamic therapy (PDT) . Materials and Method: Forty-five patients with exudative AMD who were candidate for PDT were enrolled in the study. Main outcome measures were visual acuity, lesion size on fundus fluorescein angiography (FFA) and central foveal thickness on optical coherence tomography (OCT), and the quality of life scores by using NEI-VFQ 25.Results: The mean age of the patients was 72.2±7.1 years. The mean follow-up duration was 9.1±4.5 months. The visual acuity was maintained within +3 lines in 71% of the patients. The treatment caused no significant change on the quality of life scores.Conclusions: PDT was one of the most effective treatment strategies of exudative AMD before the era of vascular endothelial growth factor antibodies. PDT was found to be safe and effective in preservation of vision and in reducing the probability of severe vision loss due to exudative AMD, but it was found to be inadequate to provide an increase in vision, and in life quality.
Özet
Giriş: Eksudatif tip yaşa bağlı makula dejenerasyonu (YBMD) için fotodinamik tedavi (FDT) uygulanan hastaların tedavi öncesi ve tedavi sonrası National Eye Institute Visual Function Questionnaire 25 (NEI-VFQ 25) ile ölçülen yaşam kalitelerini değerlendirmek ve tartışmak. Gereç ve Yöntem: Eksudatif tip YBMD'si olup FDT uygulanması planlanan 45 hasta çalışmaya dahil edildi. Temel sonuç kriterleri görme keskinliği, fundus floresein anjiyografide (FFA) lezyon boyutu, optik koherans tomografide (OKT) merkezi makula kalınlığı ve NEI-VFQ 25 yaşam kalitesi skorları idi.Bulgular: Hastaların ortalama yaşı 72.2±7.1 yıl idi. Ortalama takip süresi 9.1±4.5 ay idi. Görme keskinliği hastaların %71'inde +3 sıra içinde korundu. FDT'nin yaşam kalitesini skorlarına anlamlı etkisi olmadı.Sonuç: FDT vasküler endotelyal büyüme faktörü antikorlarından önce eksudatif tip YBMD'de en etkili tedavi idi. Güvenli bir tedavi yöntemi olan FDT eksudatif tip YBMD'ye bağlı ciddi görme kaybı riskini azaltmada ve görme keskinliğini korumada etkili, ancak görmenin ve yaşam kalitesinin artırılmasında yetersiz bulundu.